Advertisement

Cancer Causes & Control

, Volume 30, Issue 5, pp 435–441 | Cite as

Diabetes and differences in detection of incident invasive breast cancer

  • Gregory S. CalipEmail author
  • Onchee Yu
  • Denise M. Boudreau
  • Huibo Shao
  • Ruth Oratz
  • Stephen B. Richardson
  • Heather T. Gold
Brief report

Abstract

Many women diagnosed with breast cancer have chronic conditions such as diabetes that may impact other health behaviors. Our purpose was to determine if breast cancer screening and detection differs among women with and without diabetes. We conducted a cross-sectional analysis of a retrospective cohort of women aged 52–74 years diagnosed with incident stages I–III breast cancer enrolled in an integrated health plan between 1999 and 2014 with linkage to the Surveillance, Epidemiology and End Results registry (n = 2040). Screening data were taken from electronic health records. We used multivariable modified Poisson regression models with robust standard errors to estimate relative risks (RR) and 95% confidence intervals (CI) for outcomes of (i) receipt of screening in the 2 years prior to diagnosis; (ii) symptom-detected breast cancer; and (iii) diagnosis of locally advanced stage III breast cancer. Compared to women without diabetes, women with diabetes were similar with respect to receipt of screening mammography (78% and 77%), symptom-detected breast cancer (46% and 49%), and stage III diagnosis (7% and 7%). In multivariable models adjusting for age and year of diagnosis, race, BMI, Charlson comorbidity score and depression diagnosis no differences were observed in the outcomes by presence of diabetes. Further investigation is warranted to determine how diabetes acts as a mediating factor in adverse breast cancer outcomes.

Keywords

Breast cancer Diabetes Cancer screening Mammography 

Notes

Funding

This work was supported by the National Institutes of Health, National Cancer Institute, through Grant Numbers R01CA188353 (Gold) and R01CA120562 (Boudreau). Author GSC was supported by the National Institutes of Health, National Center for Advancing Translational Sciences through Grant Number KL2TR000048. The content is solely the responsibility of the authors and does not necessarily represent the official view of the National Institutes of Health.

Compliance with ethical standards

Conflict of interest

Author O.Y. has received funding for research unrelated to the contributions as co-author of this work. This funder had no role in the design, interpretation or conclusions of this study. The other authors declare that they have no conflict of interest.

Ethical approval

This study was approved by the institutional review board of the Kaiser Permanente Washington Health Research Institute.

Supplementary material

10552_2019_1166_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 14 kb)

References

  1. 1.
    American Cancer Society (2015) Breast Cancer Facts & Figures 2015-2016. American Cancer Society, AtlantaGoogle Scholar
  2. 2.
    Menke A, Casagrande S, Geiss L, Cowie CC (2015) Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA 314(10):1021–1029.  https://doi.org/10.1001/jama.2015.10029 CrossRefGoogle Scholar
  3. 3.
    Ritchie CS, Kvale E, Fisch MJ (2011) Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract 7(6):371–374.  https://doi.org/10.1200/JOP.2011.000460 CrossRefGoogle Scholar
  4. 4.
    Peairs KS, Barone BB, Snyder CF, Yeh HC, Stein KB, Derr RL, Brancati FL, Wolff AC (2011) Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. J Clin Oncol 29(1):40–46.  https://doi.org/10.1200/JCO.2009.27.3011 CrossRefGoogle Scholar
  5. 5.
    Gold HT, Makarem N, Nicholson JM, Parekh N (2014) Treatment and outcomes in diabetic breast cancer patients. Breast Cancer Res Treat 143(3):551–570.  https://doi.org/10.1007/s10549-014-2833-x CrossRefGoogle Scholar
  6. 6.
    Institute of Medicine (U.S.), Committee on Quality of Health Care in America (2013) In: Levit L, Balogh E, Nass S, Ganz PA (eds) Delivering high-quality cancer care: charting a new course for a system in crisis. Institute of Medicine, Washington (DC)Google Scholar
  7. 7.
    Beckman TJ, Cuddihy RM, Scheitel SM, Naessens JM, Killian JM, Pankratz VS (2001) Screening mammogram utilization in women with diabetes. Diabetes Care 24(12):2049–2053CrossRefGoogle Scholar
  8. 8.
    Lipscombe LL, Hux JE, Booth GL (2005) Reduced screening mammography among women with diabetes. Arch Intern Med 165(18):2090–2095.  https://doi.org/10.1001/archinte.165.18.2090 CrossRefGoogle Scholar
  9. 9.
    Tabaei BP, Herman WH, Jabarin AF, Kim C (2005) Does diabetes care compete with the provision of women’s preventive care services? Diabetes Care 28(11):2644–2649CrossRefGoogle Scholar
  10. 10.
    Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, Ipp E, Kaklamani VG, Vitolins M, Wallace R, Gunter M, Phillips LS, Strickler H, Margolis K, Euhus DM (2012) Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 30(23):2844–2852.  https://doi.org/10.1200/JCO.2011.39.7505 CrossRefGoogle Scholar
  11. 11.
    Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, Thor AD (2009) Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8(6):909–915CrossRefGoogle Scholar
  12. 12.
    Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT (2012) Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 135(3):639–646.  https://doi.org/10.1007/s10549-012-2170-x CrossRefGoogle Scholar
  13. 13.
    Bronsveld HK, ter Braak B, Karlstad O, Vestergaard P, Starup-Linde J, Bazelier MT, De Bruin ML, de Boer A, Siezen CL, van de Water B, Siezen CL, van de Laan JW, Schmidt MK (2015) Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Res 17:100.  https://doi.org/10.1186/s13058-015-0611-2 CrossRefGoogle Scholar
  14. 14.
    Wirtz HS, Buist DS, Gralow JR, Barlow WE, Gray S, Chubak J, Yu O, Bowles EJ, Fujii M, Boudreau DM (2013) Frequent antibiotic use and second breast cancer events. Cancer Epidemiol Biomark Prev 22(9):1588–1599.  https://doi.org/10.1158/1055-9965.EPI-13-0454 CrossRefGoogle Scholar
  15. 15.
    Boudreau DM, Yu O, Chubak J, Wirtz HS, Bowles EJ, Fujii M, Buist DS (2014) Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res Treat 144(2):405–416.  https://doi.org/10.1007/s10549-014-2870-5 CrossRefGoogle Scholar
  16. 16.
    Calip GS, Hubbard RA, Stergachis A, Malone KE, Gralow JR, Boudreau DM (2015) Adherence to oral diabetes medications and glycemic control during and following breast cancer treatment. Pharmacoepidemiol Drug Saf 24(1):75–85.  https://doi.org/10.1002/pds.3660 CrossRefGoogle Scholar
  17. 17.
  18. 18.
    Cancer Surveillance System (contract No. N01-CN-67009) Surveillance, Epidemiology and End Results (SEER) Program of the National Cancer Institute, Bethesda MD http://www.fhcrc.org/en/labs/phs/projects/cancer-surveillance-system.html
  19. 19.
    Surveillance Epidemiology and End Results (SEER) Program Overview of the SEER Program http://seer.cancer.gov/about/overview.html
  20. 20.
    Saunders KW, Davis RL, Stergachis A (2005) Group health cooperative. In: Strom BL (ed) Pharmacoepidemiology, 4th edn. Wiley, Hoboken, pp 223–239Google Scholar
  21. 21.
    Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH, Pharmacovigilance Study T (2012) Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 104(17):1293–1305CrossRefGoogle Scholar
  22. 22.
    Phipps AI, Ichikawa L, Bowles EJ, Carney PA, Kerlikowske K, Miglioretti DL, Buist DS (2010) Defining menopausal status in epidemiologic studies: a comparison of multiple approaches and their effects on breast cancer rates. Maturitas 67(1):60–66.  https://doi.org/10.1016/j.maturitas.2010.04.015 CrossRefGoogle Scholar
  23. 23.
    Kaiser Permanente Washington Breast Cancer Surveillance Registry. https://www.kpwashingtonresearch.org/our-research/research-areas/cancer/breast-cancer-surveillance/. Accessed 4 Mar 2019
  24. 24.
    Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRefGoogle Scholar
  25. 25.
    Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark GM, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL (2003) Staging system for breast cancer: revisions for the 6th edition of the AJCC cancer staging manual. Surg Clin North Am 83(4):803–819CrossRefGoogle Scholar
  26. 26.
    Zou G (2004) A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 159(7):702–706CrossRefGoogle Scholar
  27. 27.
    Jensen LF, Pedersen AF, Andersen B, Vestergaard M, Vedsted P (2015) Non-participation in breast cancer screening for women with chronic diseases and multimorbidity: a population-based cohort study. BMC Cancer 15:798.  https://doi.org/10.1186/s12885-015-1829-1 CrossRefGoogle Scholar
  28. 28.
    Diaz A, Kang J, Moore SP, Baade P, Langbecker D, Condon JR, Valery PC (2017) Association between comorbidity and participation in breast and cervical cancer screening: a systematic review and meta-analysis. Cancer Epidemiol 47:7–19.  https://doi.org/10.1016/j.canep.2016.12.010 CrossRefGoogle Scholar
  29. 29.
    Murto MO, Artama M, Pukkala E, Visvanathan K, Murtola TJ (2018) Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study. Int J Cancer 142(11):2227–2233.  https://doi.org/10.1002/ijc.31250 CrossRefGoogle Scholar
  30. 30.
    Alenzi EO, Madhavan SS, Tan X (2018) Association of the severity of diabetes-related complications with stage of breast cancer at diagnosis among elderly women with pre-existing diabetes. Breast Cancer Res Treat 167(1):183–193.  https://doi.org/10.1007/s10549-017-4477-0 CrossRefGoogle Scholar
  31. 31.
    Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB (2012) Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care 18(11):721–726Google Scholar
  32. 32.
    Yasmeen S, Xing G, Morris C, Chlebowski RT, Romano PS (2011) Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. Cancer 117(14):3252–3261.  https://doi.org/10.1002/cncr.25857 CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Center for Pharmacoepidemiology and Pharmacoeconomic ResearchUniversity of Illinois at ChicagoChicagoUSA
  2. 2.Kaiser Permanente Washington Health Research InstituteSeattleUSA
  3. 3.Departments of Epidemiology and PharmacyUniversity of WashingtonSeattleUSA
  4. 4.Baptist Memorial Health CareGermantownUSA
  5. 5.Department of MedicineNew York University School of MedicineNew YorkUSA
  6. 6.Department of Population HealthNew York University School of MedicineNew YorkUSA

Personalised recommendations